Olivier Loeillot, President and Chief Executive Officer (“CEO”) of Repligen as of September 1, 2024, previously served as Chief Commercial Officer (“CCO”). He joined Repligen in October 2023, and as CCO held responsibility for driving the Company’s commercial strategy and expanding the market impact Repligen’s business units. Prior to joining Repligen, Mr. Loeillot was Chief Executive Officer (“CEO”) at Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets. Mr Loeillot previously served a combined 12 years with Cytiva (a Danaher company and previously GE Healthcare Life Sciences). While at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Mr. Loeillot was also instrumental in building and leading the Enterprise Solutions business, managing the Bioprocess Asia business in Singapore, and directing the Genomics and Cellular Research division. Prior to Cytiva, Mr. Loeillot served a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. He also acted as Vice President of Sales for Lonza AG’s custom manufacturing business and led the Microbial Biopharmaceuticals group. Mr. Loeillot earned his M.S. in Chemistry in 1993 from the European High Institute of Chemistry of Strasbourg, France, and later completed a M.B.A. program at CESMA Business School of EM Lyon.